Bookmarks
Moorfields AMD Dataset 002
Population Size
9,925
People
Years
2001
Associated BioSamples
Other
Geographic coverage
https://www.geonames.org/2648147/great-britain.html
Lead time
2-6 months
Summary
Documentation
The AMD Dataset encompasses all patients who have received at least one injection of either Lucentis (ranibizumab) or Eylea (aflibercept) to treat age-related macular degeneration (AMD) at Moorfields Eye Hospital - a leading provider of eye health services in the UK and a world-class centre of excellence for ophthalmic research and education.
These therapies began at Moorfields in 2007, however, the dataset will include any imaging or clinical metadata that is available for these patients prior to that time (for example in patients who were initially monitored for the early or intermediate forms of this disease prior to receiving treatment). Also of note, this dataset will include data from both eyes in each case - for example, it will include data from fellow eyes that are not receiving injections. For these reasons, the dataset will include longitudinal data from a mixture of eyes with both “dry” and “wet” AMD.
Clinical metadata includes information regarding:
- patient demographics
- visual acuities (predominantly measured with Early Treatment Diabetic Retinopathy Study (ETDRS) charts)
- diabetic retinopathy grading
- intravitreal therapies and ocular surgeries
Additional information is provided in the ‘technical details’ tab.
The AMD dataset includes eye imaging modalities, such as:
- Optical coherence tomography (CSO, Heidelberg, Optos, Topcon, Zeiss)
- Colour fundus photographs (Topcon, Zeiss)
- Ultra-wide field photographs (Optos, Zeiss)
- Iris photographs (CSO, Zeiss)
- Keratoscope topography (CSO)
- Infrared photographs (Heidelberg, Topcon, Zeiss)
- Fluorescein angiography (Heidelberg, Optos, Topcon, Zeiss)
- Indocyanine green angiography (Heidelberg, Optos, Topcon)
- Fundus autofluorescence (Heidelberg, Optos, Zeiss)
Imaging data from CSO is subject to additional approvals.
As of July 2024, the dataset consisted of 12,641 eyes receiving Lucentis or Eylea for AMD, 220,219 injection episodes, and 2,943,338 ophthalmic images. This is the largest single centre database from patients with AMD and covers more than a decade of follow-up for these patients.
Dataset type
Dataset sub-type
Dataset population size
Associated media
Keywords
Observations
Observed Node | Disambiguating Description | Measured Value | Measured Property | Observation Date |
|---|---|---|---|---|
Persons | 19,785 Eyes with 2,943,338 Images 12,641 Eyes with 220,219 Injections (Lucentis/Eylea) | 9925 | Patients | 01 Jul 2024 |
Provenance
Purpose of dataset collection
Collection source setting
Patient pathway description
Image contrast
Biological sample availability
Structural Metadata
Details
Publishing frequency
Version
Modified
08/10/2024
Citation Requirements
Coverage
Start date
01/03/2001
Time lag
Geographic coverage
Minimum age range
Maximum age range
Follow-up
10 Years
Accessibility
Language
Controlled vocabulary
Format
Data Access Request
Dataset pipeline status
Access rights
Time to dataset access
Access request cost
Access method category
Access service description
INSIGHT is developing its data access environment for researchers. INSIGHT releases anonymised data, under strict data licence arrangements, to external secure environments, subject to appropriate due diligence and contracting.
Jurisdiction
Data use limitation
Data use requirements
Data Controller